Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.41 |
| ▸ | LPL | P06858 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16538273 | 0.89 | LPL (0.40) | CXCR2LPLLIPGSLC6A4SLC6A3 | |
| SCHEMBL29453759 | 0.85 | TSHR (0.46) | CXCR2LPLLIPGCYP1A2NPC1 | |
| SCHEMBL19893998 | 0.85 | TSHR (0.46) | CXCR2LPLLIPGCYP1A2NPC1 | |
| SCHEMBL27033334 | 0.84 | DGAT1 (0.43) | LPLLIPGDGAT1 | |
| SCHEMBL1717269 | 0.84 | CYP46A1 (0.43) | PDK2TSHRDGAT1KDM4EALDH1A1 | |
| SCHEMBL3454613 | 0.84 | KDM4E (0.46) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL257899 | 0.84 | CA12 (0.53) | PDK2TSHRDGAT1KDM4EALDH1A1 | |
| SCHEMBL24265381 | 0.84 | CXCR2 (0.43) | CXCR2LPLLIPGSMN1; SMN2KEAP1 | |
| SCHEMBL18107886 | 0.83 | CA12 (0.37) | PDK2TSHRDGAT1KDM4EALDH1A1 | |
| SCHEMBL19946115 | 0.83 | KDM4E (0.49) | PLA2G2ACYP1A2NPC1RAB9ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| WO-2023179600-A1 | NOVEL SUBSTITUTED MACROHETEROCYCLIC COMPOUNDS AND USE THEREOF | 杭州德睿智药科技有限公司 | 2023-09-28 | — | — | WO | disclosed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | disclosed |
| WO-2022222995-A1 | PICOLINAMIDE COMPOUND | 南京明德新药研发有限公司 | 2022-10-27 | — | — | WO | disclosed |
| US-11324724-B2 | N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-10 | — | — | US | disclosed |
| CN-110357832-B | Preparation method of aromatic amine compound, EphB4 kinase inhibitor and derivatives thereof | 武汉大学 | 2022-03-15 | — | — | CN | disclosed |
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | disclosed |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-11 | — | — | US | disclosed |
| EP-3668864-B1 | N-(2,2-DIFLUOROETHYL)-N-[(PYRIMIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2021-07-21 | — | — | EP | disclosed |
| US-20130137672-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-30 | — | — | US | disclosed |
| WO-2012145581-A1 | DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-26 | — | — | WO | disclosed |
| EP-2491034-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491031-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491038-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-16 | — | — | US | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011050202-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050200-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050198-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | CXCR2 778/4885LPL 4372/4885LIPG 4686/4885 |
| US-11324724-B2 | N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides | HCRTR2, HCRTR1, CNR2 | CXCR2 572/4885LPL 1450/4885LIPG 3585/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | CXCR2 778/4885LPL 4372/4885LIPG 4686/4885 |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | CXCR2 864/4885LPL 4471/4885LIPG 4601/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | CXCR2 778/4885LPL 4372/4885LIPG 4686/4885 |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | CXCR2 778/4885LPL 4372/4885LIPG 4686/4885 |
| US-20130137672-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | CXCR2 718/4885LPL 4533/4885LIPG 4662/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | CXCR2 778/4885LPL 4372/4885LIPG 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.